BriaCell Therapeutics Corp. (BCTX) Short-Term Debt to Equity

Graphic logo of briacell.com (BCTX)

BriaCell Therapeutics (BCTX) is a biopharmaceutical player in oncology utilizing a high upfront cost model to secure future monopoly patent revenues. The brand is valued by the scientific community for developing innovative immunotherapy methods for breast cancer. The market capitalization trend on GURU.Markets is currently at 0.00. Business defensibility is increasing alongside the development of its AI platform, although a full market barrier will only emerge following FDA certification.

BCTX - BriaCell Therapeutics Corp. Short-Term Debt to Equity Ratio over the range 07/04/2022 - 10/31/2026

Financial and market metric breakdowns for briacell.com (BCTX)

- stock quotes and analyst forecast:
Stock Price BriaCell Therapeutics Corp|BCTX - Analyst Consensus Forecast
- market capitalization details:
Market Value BriaCell Therapeutics Corp.|BCTX - Business Value
- balance sheet equity data:
Book Value per Share BriaCell|BCTX - Company Net Assets|Market Capitalization to Book Value Ratio briacell.com|BCTX - Company Assets
- business debt structure and liquidity details:
Debt to Equity BriaCell Therapeutics|BCTX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio BriaCell|BCTX - Aggregate Debt Obligations|Debt to Book Value BriaCell Therapeutics Corp.|BCTX - Company Long-Term Liabilities|Company Short-Term Debt BriaCell|Quick Liquidity briacell.com
- earnings and market ratios statistics:
BCTX - Net Income
Fundamental valuation:BriaCell Therapeutics Corp BCTX
Signature product of BriaCell Therapeutics Corp.

This ratio determines the company's dependence on short-term borrowings relative to its equity, allowing for an assessment of solvency risk amid market volatility. By analyzing the change in the share of short-term loans within the capital structure, an investor can discern the financial stability of BriaCell Therapeutics (BCTX), which, thanks to a robust liquidity reserve and confidence in management, successfully finances the development of immunotherapy without critical debt pressure.

Competitors of BriaCell Therapeutics

Short-Term Debt to Capital MRUS|Short-Term Debt to Capital Immutep Corp (IMMP)|Short-Term Debt to Equity Anixa Biosciences, Inc. ANIX|ATOS: Short-Term Debt to Capital Ratio|Context Tx - Short-Term Debt to Capital|Mersana Therapeutics (MRSN) - Short-Term Debt to Equity Ratio|EPIX: Short-Term Debt to Capital|Current Liabilities to Capital QT Imaging, Inc. (QTI)